Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other neoplasm 1

Conditions

Precancerous Conditions 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 13Biopsy 13fludarabine phosphate 9Whole-Body Irradiation 9Surveys and Questionnaires 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Polymerase Chain Reaction 7Mycophenolic Acid 7Early Intervention, Educational 7Tacrolimus 6Gene Expression Profiling 6Educational Status 6Colposcopy 6Carboplatin 6fludarabine 5Paclitaxel 5Microarray Analysis 5Methotrexate 5Methods 5Melphalan 5Immunohistochemistry 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Iloprost × Other neoplasm × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡